TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Research to Develop PET and SPECT Ligands for Brain Imaging Encouraged (SBIR Award)

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), the National Institute on Deafness and Other Communication Disorders (NIDCD), the National Institute of Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), the National Institute on Aging (NIA), and the National Institute of Environmental Health Sciences (NIEHS) invite Small Business Innovation Research (SBIR) grant applications to develop novel radioligands for positron emission tomography (PET) and single photon emission tomography (SPECT) imaging in human brain.*

The use of radiotracers for imaging molecular events in preclinical and clinical studies is essential for understanding the biological basis of normal brain function and the pathophysiology of brain disorders. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials.

This initiative is intended to stimulate the development of radioligands for molecular targets that are of broad interest to the scientific community. Use of these radioligands is expected to accelerate research on identifying and characterizing the neural circuits and pathways implicated in the pathophysiology of brain disorders, and to facilitate the identification of new therapeutic targets and the development of new compounds as potential therapeutic agents. Molecular targets for which radioligands are needed include receptors, transporters, enzymes, and intracellular targets.

For more information, potential applicants should contact Technology Development Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2139, Bethesda, MD 20892; telephone: 301-496-1779; fax: 301-402-1501; e-mail:

*For a more detailed description of this program announcement, please visit the NIH web site at: